摘要
囊性纤维化(CF)主要是由蛋白质错误折叠和一个称为囊性纤维化跨膜传导调节(CFTR)的质膜阴离子通道功能的丧失所引起的。最常见的致突变基因,F508del,其导致CFTR严重的构象缺陷。细胞伴侣机械对CFTR的生物合成和质量控制起着的重要作用。通过调节的细胞分子伴侣机械零部件的表达来提高突变的CFTR细胞表面表达功能,这已进行了多次尝试。由于F508del CFTR缺陷导致严重的内在的折叠,这种方法的有效性在很大程度上被低估。此外,伴侣机械本身的伴侣扰动和其他生理上的重要蛋白的影响,可能会导致潜在的严重副作用。针对扰乱伴侣-CFTR相互作用的方法表现出更大的效能,并能兼容小分子药物的发现和基因治疗。针对扰乱伴侣-CFTR相互作用的方法表现出更大的效能,并能兼容小分子药物的发现和基因治疗。分子伴侣在调节炎症和免疫中发挥重要作用,它们可能是控制患者的呼吸道感染和炎症的潜在靶标。如果这种影响可以通过协同分子伴侣介导的CFTR的生物合成和质量控制增效,那么将会有更有效的新治疗CF肺病方案出现。
关键词: 囊性纤维化跨膜电导调节因子(CFTR),囊性纤维化,药物发现,F508del,免疫,炎症,分子伴侣,蛋白质折叠
图形摘要
Current Drug Targets
Title:Targeting Molecular Chaperones for the Treatment of Cystic Fibrosis: Is It a Viable Approach?
Volume: 16 Issue: 9
Author(s): Ashley Heard, Jake Thompson, Jessica Carver, Michelle Bakey and X. Robert Wang
Affiliation:
关键词: 囊性纤维化跨膜电导调节因子(CFTR),囊性纤维化,药物发现,F508del,免疫,炎症,分子伴侣,蛋白质折叠
摘要: Cystic Fibrosis (CF) is largely caused by protein misfolding and the loss of function of a plasma membrane anion channel known as the cystic fibrosis transmembrane conductance regulator (CFTR). The most common CF-causing mutation, F508del, leads to severe conformational defect in CFTR. The cellular chaperone machinery plays an important role in CFTR biogenesis and quality control. Multiple attempts have been made to improve the cell surface functional expression of the mutant CFTR by modulating the expression of components of the cellular chaperone machinery. The efficacy of such an approach has been low largely due to the severe intrinsic folding defects of the F508del CFTR. Moreover, the impact of chaperone perturbation on the chaperone machinery itself and on other physiologically important proteins might lead to potentially severe side effects. Approaches aimed at disrupting chaperone-CFTR interactions show greater efficacy, and are compatible with small-molecule drug discovery and gene therapy. Combination between chaperone modulators and F508del correctors might further enhance potency and specificity. As molecular chaperones play important roles in regulating inflammation and immunity, they can be potential targets for controlling airway infection and inflammation in patients. If such effects can be synergized with chaperone-mediated regulation of CFTR biogenesis and quality control, more efficacious therapeutics will be developed to combat CF lung disease.
Export Options
About this article
Cite this article as:
Ashley Heard, Jake Thompson, Jessica Carver, Michelle Bakey and X. Robert Wang , Targeting Molecular Chaperones for the Treatment of Cystic Fibrosis: Is It a Viable Approach?, Current Drug Targets 2015; 16 (9) . https://dx.doi.org/10.2174/1389450116666150518102831
DOI https://dx.doi.org/10.2174/1389450116666150518102831 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Small Molecule Toxins Targeting Tumor Receptors
Current Pharmaceutical Design Development of a Registry for Down Syndrome in the Gulf Area of the Middle East
Applied Clinical Research, Clinical Trials and Regulatory Affairs Nanocarriers: A General Strategy for Enhancement of Oral Bioavailability of Poorly Absorbed or Pre-Systemically Metabolized Drugs
Current Drug Metabolism Phytochemical-Mediated Glioma Targeted Treatment: Drug Resistance and Novel Delivery Systems
Current Medicinal Chemistry Kinin Receptors in Vascular Biology and Pathology
Current Vascular Pharmacology Phosphodiesterase-5 Inhibitors: Future Perspectives
Current Pharmaceutical Design Hematopoietic Stem Cells Therapies
Current Stem Cell Research & Therapy Jatropha Curcas L., A Multipurpose Stress Resistant Plant with a Potential for Ethnomedicine and Renewable Energy
Current Pharmaceutical Biotechnology Nonstandard Drugs and Feasible New Interventions for Autoimmune Hepatitis: Part I
Inflammation & Allergy - Drug Targets (Discontinued) Statistical Optimization of Pharmacogenomics Association Studies: Key Considerations from Study Design to Analysis
Current Pharmacogenomics and Personalized Medicine Psoriasin, A Multifunctional Player in Different Diseases
Current Protein & Peptide Science Trends in Patents of Enzymatic Biomarkers for Early Detection of Bacteria
Recent Patents on Biomarkers Adhesion Dependent Signalling in the Tumour Microenvironment: The Future of Drug Targetting
Current Pharmaceutical Design Mast Cells in Lung Homeostasis: Beyond Type I Hypersensitivity
Current Respiratory Medicine Reviews Proceedings of the 1<sup>st</sup> Puerto Rico Biobanking Workshop
Reviews on Recent Clinical Trials Novel Research Strategies of Benzimidazole Derivatives: A Review
Mini-Reviews in Medicinal Chemistry Serpins for Diagnosis and Therapy in Cancer
Cardiovascular & Hematological Disorders-Drug Targets Significance of Prion and Prion-Like Proteins in Cancer Development, Progression and Multi-Drug Resistance
Current Cancer Drug Targets Pharmacogenetics of Irinotecan Disposition and Toxicity: A Review
Current Clinical Pharmacology Amygdalin from Apricot Kernels Induces Apoptosis and Causes Cell Cycle Arrest in Cancer Cells: An Updated Review
Anti-Cancer Agents in Medicinal Chemistry